R.SylvesterJ
These agents could be used in combination with gut-targeted therapies to provide a more comprehensive approach to mitigating cognitive dysfunction post-I/R (Liu et al., 2023)
doi: 10.7150/thno.67167 Summary Keywords polycystic ovary syndrome, gut microbiota, metabolic disorders, insulin resistance, bile acids Citation Li J, Qiao J, Li Y, Qin G, Xu Y, Lao K, Wang Y, Fan Y, Tang P and Han L (2025) Metabolic disorders in polycystic ovary syndrome: from gut microbiota biodiversity to clinical intervention
Chronic pain: an update on burden, best practices, and new advances
Standalone 250mg capsules without co-factors avoid karein
Mitochondrial metabolism and substrate competition in the aging Fischer rat heart